Healthy Clinical Trial
Official title:
A Single-center, Randomized, Double-blinded and Placebo-controlled Clinical Study in Healthy Chinese Subjects to Evaluate the Pharmacokinetics, Safety and Tolerability of LXI-15028 After Receiving Escalating Single Oral Doses of LXI-15028 at 50 mg, 100 mg and 200 mg and Multiple Oral Doses of LXI-15028 at 100 mg
"This study is a single-center, randomized, double-blinded and placebo-controlled trial designed not only to assess pharmacokinetics, safety and tolerability of LXI-15028 but also to evaluate the pharmacokinetic characteristics of main metabolite M1 in vivo in 38 healthy adult Chinese subjects after receiving escalating single oral doses of 50 mg, 100 mg and 200 mg and multiple oral doses of 100 mg of LXI-15028.
This study includes 3 dose groups which are 50 mg (Group 1), 100 mg(Group 2) and 200 mg(Group
3) respectively. For 50 mg and 200 mg dose groups, each is planned to enroll 12 healthy
subjects (investigational drug :placebo=10:2), half males and half females. Five subjects of
each gender will receive LXI-15028, while 1 subject of each gender will receive placebo; 100
mg dose group plans to enroll 14 healthy subjects (investigational drug:placebo=10:4), half
males and half females. Five subjects of each gender will receive LXI-15028, while 2 subjects
of each gender will receive placebo. Intra-group randomization will be implemented in each
dose group; each subject will receive either LXI-15028 or placebo.
This study includes 2 parts of single-dose and multiple-dose administration. The single-dose
study will use gradually escalation dosing to evaluate the 3 doses of 50 mg, 100 mg and 200
mg. Within 4 days after each dose is administered, the investigators will assess the safety
and tolerability data to decide whether to proceed with the next escalated single dose.
Within 4 days of 200 mg single-dose administration, the investigators will assess the safety
and tolerability data to decide whether to proceed with 100 mg multiple-dose study.
Multiple-dose study will be investigated in 100 mg group only.
The study consists of screening period, treatment period and follow-up in each dose group.
The treatment period in 50 mg and 200 mg dose groups include single-dose administration only.
While the treatment period in 100 mg dose group includes both single-dose and multiple-dose
administration. The subjects in 100 mg dose group will enter multiple-dose period following
completing single-dose period.
In escalated single-dose study, the subjects in each dose group will receive single oral dose
of 50 mg LXI-15028 tablet or 1 matching placebo tablet at fasted state, or 100 mg LXI-15028
tablet or matching placebo 1 tablet, or 2 100 mg LXI-15028 tablets or 2 matching placebo
tablets. Blood samples will be collected before administration (0h), and 15 min (0.25h), 30
min (0.5h), 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 48h and 72h after administration.
In multiple-dose study, the subjects will continuously receive oral 100 mg LXI-15028 tablet
or 1 matching placebo tablet once daily (QD) for 10 times. Blood samples of trough
concentration will be collected before the 8th to 10th administration (0h) in multiple-dose
study. And blood samples will be collected at 15 min (0.25h), 30 min (0.5h), 1h, 1.5h, 2h,
2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 48h and 72h after the 10th administration.
The collected blood samples will be processed to obtain plasma. Liquid Chromatographic(LC)
/Mass Spectra(MS)/Mass Spectra (MS) method will be used to determine plasma concentrations of
LXI-15028 and its major metabolite M1 in order to evaluate the pharmacokinetic
characteristics of LXI-15028 and its metabolite M1 after oral administration of LXI-15028
tablet.
The safety will be assessed by physical examination, vital signs, ECG, laboratory
examinations and adverse events in subjects receiving LXI-15028 tablet.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |